Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Understanding the Lethal Variant of Prostate Cancer: Power of Examining Extremes

(2011) A. Aparicio et al.   Cancer Discovery

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

(2011) H. Beltran et al.   Cancer Discovery

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

(2009) R. B. Cohen et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors

(2009) Neeltje Steeghs et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer

(2008) W. L. Dahut et al.   CLINICAL CANCER RESEARCH

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY